Literature DB >> 581876

Correlation between thyroid stimulators and 3,5,3'-triiodothyronine suppressibility in patients during treatment for hyperthyroidism with thionamide drugs: comparison of assays by thyroid-stimulating and thyrotropin-displacing activities.

N Kuzuya, S C Chiu, H Ikeda, H Uchimura, K Ito, S Nagataki.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 581876     DOI： 10.1210/jcem-48-4-706

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN： 0021-972X            Impact factor:   5.958


× No keyword cloud information.
  14 in total

1.  Changes in thyrotropin binding inhibiting immunoglobulins (TBII) in sera of patients with Graves' disease at the time of relapse or exacerbation.

Authors:  H Uchimura; N Akimoto; T Mitsuhashi; K Kubota; N Kuzuya; Y Imai; H Ikeda; F Matsuzaki; L F Kumagai
Journal:  J Endocrinol Invest       Date:  1986-02       Impact factor: 4.256

2.  Graves' disease and Hashimoto's thyroiditis: effects of high doses of antithyroid drugs on thyroid autoantibody levels.

Authors:  J H Romaldini; M C Werner; H F Rodrigues; V L Teixeira; R S Werner; C S Farah; N Bromberg
Journal:  J Endocrinol Invest       Date:  1986-06       Impact factor: 4.256

Review 3.  The thyrotrophin receptor.

Authors:  S W Manley; A Knight; D D Adams
Journal:  Springer Semin Immunopathol       Date:  1982

4.  Thyroid hormone secretion is more sensitive than thyroid cyclic AMP accumulation to stimulation with LATS in mice in vitro and in vivo.

Authors:  H Ikeda; S C Chiu; N Kuzuya; H Uchimura; S Nagataki
Journal:  J Endocrinol Invest       Date:  1984-02       Impact factor: 4.256

5.  Syndrome of persisting thyroid stimulating immunoglobulins and growth promotion of goiter combined with low thyroxine and high triiodothyronine serum levels in drug treated Graves' disease.

Authors:  K W Wenzel; J R Lente
Journal:  J Endocrinol Invest       Date:  1983-10       Impact factor: 4.256

6.  TSH-displacing activity versus TSH-binding inhibiting activity of immunoglobulins from patients with Graves' disease.

Authors:  E Macchia; G F Fenzi; F Monzani; L Bartalena; F Lippi; V Aloisio; C Cupini; L Baschieri; A Pinchera
Journal:  J Endocrinol Invest       Date:  1983-10       Impact factor: 4.256

7.  Concentration-dependent regulation of thyrotropin receptor function by thyroid-stimulating antibody.

Authors:  Takao Ando; Rauf Latif; Terry F Davies
Journal:  J Clin Invest       Date:  2004-06       Impact factor: 14.808

Review 8.  Clinical pharmacokinetics of antithyroid drugs.

Authors:  J P Kampmann; J M Hansen
Journal:  Clin Pharmacokinet       Date:  1981 Nov-Dec       Impact factor: 6.447

9.  Effect of plasmapheresis and steroid treatment on thyrotropin binding inhibitory immunoglobulins in a patient with exophthalmos and a patient with pretibial myxedema.

Authors:  N Kuzuya; L J DeGroot
Journal:  J Endocrinol Invest       Date:  1982 Nov-Dec       Impact factor: 4.256

10.  The prognostic value of parallel measurements of thyrotropin binding inhibiting immunoglobulins (TBII) and thyroid adenylate cyclase stimulating antibodies (TSAb) in Graves' disease after longterm antithyroid treatment.

Authors:  H Bliddal; K Bech; K Siersbaek-Nielsen; T Friis
Journal:  J Endocrinol Invest       Date:  1983-08       Impact factor: 4.256
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.